Vivek Gupta, Ph.D., FAAPS

  1. Home
  2. Academics
  3. Our Faculty
  4. Vivek Gupta, Ph.D., FAAPS
Associate Professor, Pharmaceutical Sciences (Industrial Pharmacy)
Pharmaceutical Sciences
College of Pharmacy and Health Sciences
PhD, Pharmaceutical Sciences, Texas Tech University Health Sciences Center (2010)BS, Pharmaceutical Sciences, Jamia Hamdard (University) (2003)Post-Doctoral Training: Department of Chemical Engineering, University of California Santa Barbara (2011-2013)

LinkedIn Profile

Research Website

Dr. Vivek Gupta is a pharmaceutical scientist and innovator specializing in nanomedicine and advanced drug delivery. His research focuses on engineering organ-targeted delivery systems to enhance the pharmacokinetics, efficacy, and translational potential of small molecules, peptides, and biologics, particularly through non-invasive routes such as inhalation and intranasal administration. His work spans pulmonary diseases, CNS disorders, and oncology, with a strong emphasis on overcoming biological barriers and improving site-specific drug deposition.

Dr. Gupta has authored 120+ peer-reviewed publications, with 7,000+ citations, and is an inventor on >30 submitted/published patent applications, reflecting the impact of his work in translational drug delivery. He is a recipient of multiple competitive research awards and has been recognized as a Fellow of the American Association of Pharmaceutical Scientists (FAAPS) for his contributions to the field.

He serves in national leadership roles within AAPS, including advancing scientific programming and career development initiatives. A dedicated mentor and academic leader, Dr. Gupta is committed to driving innovation at the interface of nanotechnology, drug delivery, and patient-centered therapeutic outcomes.

Teaching Interests:

Pharmaceutics, Pharmacokinetics, Pharmaceutical Compounding, Targeted Drug Delivery, Pharmaceutical Analysis


Research Interests:

Inhalation, Pulmonary delivery, Rare Diseases, Pharmaceutical scalability, Respiratory diseases, Drug Repurposing and Repositioning, Mesothelioma, Pulmonary hypertension, Pulmonary fibrosis, Lung cancer


Courses Taught:

Undergraduate

BMS 1000 SEMINARS IN BIOMEDICAL SCIENCES

PHS 4601 EXTEMPORANEOUS COMPOUNDING

PHS 4602 BIOPHA & BASIC PHARMACOKINETICS

PHS 3601 PHARMACEUTICS – I

PHS 3151 CALCULATIONS IN PHARMACY PRACTICE

Graduate

IPP 250 TARGETED DRUG DELIVERY SYSTEMS

IPP 233 INDUSTRIAL PHARM JOURNAL CLUB

PHS 256 PHARMACEUTICAL ANALYSIS

 

Current Lab Personnel:

  • Naveen Rajana, PhD – Postdoctoral Fellow
  • Zia Uddin Masum – PhD Candidate
  • Sravani Ravula – PhD Candidate
  • Suman Choudhary – PhD Candidate
  • Sanjana Durve – PhD Candidate
  • Reshma Sarkar – PhD Candidate

Select Publications

Journal Articles

Selected Publications (2021 onwards)

For full list, visit PUBMED or GOOGLE SCHOLAR (>7,000 Citations, H-index – 45)

  1. Rajana N, Ravula S, Quadros M, Mokashi M, Islam MA, Mehta DA, Alkyam M, Mehra NK, Perron JC, Kumar S, Sanhueza CA, Gupta V* (2026). Ribociclib-loaded Folic Acid Conjugated Chitosan-Polycaprolactone Hybrid Nanoparticles for the Management of Glioblastoma. Biomaterials Advances (Accepted April 30, 2026).

  2. Mokashi M, Goyal M, Rajana N, Gupta V* (2026). Liposomal Amodiaquine for Localized Therapy of Non-Small Cell Lung Cancer. AAPS PharmSciTech (Available online March 2, 2026).

  3. Quadros M, Rajana N, Gupta V* (2026). Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment. AAPS PharmSciTech (Available online March 2, 2026).

  4. Gadhave D, Quadros M, Goyal M, Ugale AR, Gupta V* (2025). A Microemulsion for Oral Delivery of Nintedanib – QbD-Enabled Formulation Development, In-vitro Characterization & In-vivo Pharmacokinetic Assessment. The AAPS Journal (Available online August 11, 2025).

  5. Masum ZU, Spoors GP, Burke MD*, Gupta V* (2025). Novel Polymorphic Patterns for Elacestrant Dihydrochloride. Pharmaceutics (Accepted May 30, 2025).

  6. Gadhave DG, Quadros M, Ravula S, Ugale AR, Alkyam M, Perron JC, Gupta V* (2025). Quality by Design Enabled Development and In-vitro Assessment of a Nanoemulgel Formulation for Nose-to-Brain Delivery of Nintedanib for Glioblastoma Multiforme Treatment. International Journal of Pharmaceutics 676:May 2025:125632.

  7. Quadros M, Goyal M, Chauhan G, Gadhave D, Gupta V* (2025). An Inhaled Nanoemulsion Encapsulating a Herbal Drug for Non-small Cell Lung Cancer (NSCLC) Treatment. Pharmaceutics 17(5):540.

  8. Wang X, Choudhary SM, Chauhan G, Muth A, Gupta V* (2024). Transferrin-Conjugated Polymeric Nanoparticles for Receptor-Mediated Delivery of Resveratrol-Cyclodextrin Complex in Non-Small Cell Lung Cancer (NSCLC) Cells. Journal of Drug Delivery Science and Technology 105:March 2025:106588.

  9. Kulkarni NS, Chauhan G, Quadros M, Gadhave DG, Gupta V* (2024). Development and In-vitro Evaluation of Doxorubicin-loaded Methacrylate Gelatin (GelMa) Hydrogels for the Treatment of Malignant Pleural Mesothelioma. Pharmaceutical Research 41(12):2331-2345.

  10. Chauhan G, Shaik AA, Sawant SS, Diwan R, Mokashi M, Goyal M, Shukla SK, Kunda NK, Gupta V* (2024). Continuously Producible Aztreonam-loaded Inhalable Lipid Nanoparticles for Cystic Fibrosis-Associated Pseudomonas aeruginosa Infections – Development and In-vitro Characterization. Biomaterials Advances (Previously Mat. Sci. Eng. C) 166:January 2025:214027.

  11. Masum ZU, Spoors PG, Burke MD*, Gupta V* (2024). Identification of New Polymorphic Patterns for Elacestrant-2HCl. Preprints (Preprint available June 19, 2024; 10.20944/preprints202406.1250.v1).

  12. Masum ZU, Spoors PG, Cruskie M, Bolger J, McKenzie J, Sheth P, Edwards R, Eberlin A, Markey M, Gupta V* (2024). Stability and Polymorphic Characterization of Elacestrant-2HCl. Research Square (Preprint available June 17, 2024; 10.21203/rs.3.rs-4580437/v1).

  13. Chauhan G, Wang X, Quadros M, Vats M, Gupta V* (2024). Chitosan/Bovine Serum Albumin Layer-by-Layer Assembled Particles for Non-invasive Inhaled Drug Delivery to the Lungs. International Journal of Biological Macromolecules 271, Part 2:June 2024:132526.

  14. Gadhave DG, Quadros M, Ugale AR, Goyal M, Ayehunie S, Gupta V* (2024). Mucoadhesive Chitosan-Poly (Lactic-co-Glycolic Acid) Nanoparticles for Intranasal Delivery of Quetiapine – Development & Characterization in Physiologically Relevant 3D Tissue Models. International Journal of Biological Macromolecules 267, Part 2:May 2024:131491.

  15. Shukla SK, Goyal M, Kanabar DD, Ayehunie S, Deore B, Sanhueza CA, Muth A, Gupta V* (2024). Exploring the Enhanced Stability and Therapeutic Efficacy of Sorafenib-Cyclodextrin Inclusion Complex. Journal of Molecular Liquids 401:May 2024:124701.

  16. Wang X, Goyal M, Gadhave DG, Gupta V* (2024). Inhaled Nintedanib Nanoparticles for Enhanced Efficacy in Idiopathic Pulmonary Fibrosis (IPF) Treatment – Evidence in Clinically Relevant In-Vitro Models. Journal of Drug Delivery Science & Technology 95:May 2024:105615.

  17. Yousry C, Goyal M, Gupta V* (2024). Excipients for Novel Inhaled Dosage Forms – An Overview. AAPS PharmSciTech 25:36.

  18. Kanabar DD, Kane E, Chavan T, LaFlamme T, Suarez E, Goyal M, Gupta V, Spratt D, Muth A (2023). Synthesis and Evaluation of 2,5-Substituted Pyrimidines as Small Molecule Gankyrin Binders. Future Medicinal Chemistry 16(3):239-251.

  19. Wang X, Chauhan G, Gadhave DG, Gupta V* (2023). Development and Optimization of Inhaled Nintedanib-loaded PLGA Nanoparticles Using Scalable High-Pressure Homogenization Technique. Journal of Drug Delivery Science & Technology 91(9):105233.

  20. Gadhave DG, Quadros M, Ugale AR, Goyal M, Gupta V* (2023). A Nanoemulgel for Nose-to-Brain Delivery of Quetiapine – QbD-Enabled Formulation Development & In-vitro Characterization. International Journal of Pharmaceutics 648:Dec 2023:123566.

  21. Goyal M, Tulsyan G, Kanabar DD, Chavan T, Muth A, Gupta V* (2023). Poly Vinyl Pyrrolidone (PVP) based Inhaled Delivery Carriers for Olaparib for Non-Small Cell Lung Cancer (NSCLC) Treatment. Journal of Drug Delivery Science & Technology 87:Sept 2023:104767.

  22. Chauhan G, Wang X, Yousry C, Gupta V* (2023). Scalable Production and In-vitro Efficacy of Inhaled Erlotinib Nano-emulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC). Pharmaceutics 15(3):996.

  23. Parvathaneni V, Shukla SK, Gupta V* (2023). Development and Characterization of Folic Acid Conjugated Amodiaquine-loaded Nanoparticles – Efficacy in Cancer Treatment. Pharmaceutics15(3):1001.

  24. Quadros M, Gupta V* (2023). Updated Landscape of Inhaled Medications to Combat COVID-19. Therapeutic Delivery 14(1):5-9.

  25. Wang X, Chauhan G, Tacderas AL, Muth A, Gupta V* (2023). Surface-Modified Inhaled Microparticle-encapsulated Celastrol for Enhanced Efficacy in Malignant Pleural Mesothelioma. International Journal of Molecular Sciences 24(6):5204.

  26. Parvathaneni V, Chilamakuri R, Kulkarni NS, Baig NF, Agarwal S, Gupta V* (2022). Exploring Amodiaquine’s Repurposing Potential in Breast Cancer Treatment – Assessment of In-vitro Efficacy & Mechanism of Action. International Journal of Molecular Sciences 23(19):11455.

  27. Sarvepalli S, Parvathaneni V, Chauhan G, Shukla SK, Gupta V* (2022). Inhaled Indomethacin-loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC). Pharmaceutical Research 39(11):2801-2815.

  28. Parvathaneni V, Chilamakuri R, Kulkarni NS, Wang X, Agarwal S, Gupta V* (2022). Repurposing Clofazimine for Malignant Pleural Mesothelioma Treatment – In-vitro Assessment of Efficacy and Mechanism of Action. Life Sciences 306:Oct 2022:120843.

  29. Shukla SK, Nguyen V, Goyal M, Gupta V* (2022). Cationically Modified Inhalable Nintedanib Niosomes: Enhancing Therapeutic Activity Against Non-Small Cell Lung Cancer. Nanomedicine 17(13):935-958.

  30. Kanabar D, Goyal M, Kane E, Chavan T, Kabir A, Wang X, Shukla S, Almasri J, Goswami S, Osman G, Kokolis M, Spratt D, Gupta V, Muth A* (2022). Small Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer. Journal of Medicinal Chemistry 65(13):8975-8997.

  31. Kulkarni NS, Gupta V* (2022). Repurposing Therapeutics for Malignant Pleural Mesothelioma (MPM) – Updates on Clinical Translation and Future Outlook. Life Sciences 304:Sept 2022:120716.

  32. Kulkarni NS, Chauhan G, Goyal M, Sarvepalli S, Gupta V* (2022). Development of Gelatin Methacrylate (GelMa) Hydrogels for Versatile Intracavitary Applications: In-vitro Characterization and Ex-vivo Performance Assessment. Biomaterials Science (Invited article for Biomaterials Science Emerging Investigators Series) 10:4492-4507.

  33. Shukla SK, Sarode A, Wang X, Mitragotri S, Gupta V* (2022). Particle Shape Engineering for Improving Safety and Efficacy of Doxorubicin – A Case Study of Rod-Shaped Carriers in Resistant Small Cell Lung Cancer. Biomaterials Advances (Previously Materials Science & Engineering C) 137:212850.

  34. Sawant SS, Patil SM, Shukla SK, Kulkarni NS, Gupta V, Kunda NK (2021). Pulmonary Delivery of Osimertinib Liposomes for Non-Small Cell Lung Cancer Treatment: Formulation Development and In-vitro Evaluation. Drug Delivery and Translational Research 12:2474-2487.

  35. Parvathaneni V, Shukla SK, Kulkarni NS, Gupta V* (2021). Development and Characterization of Inhalable Transferrin Functionalized Amodiaquine Nanoparticles – Efficacy in Non-small Cell Lung Cancer (NSCLC) Treatment. International Journal of Pharmaceutics 608:121038.

  36. Shukla SK, Sarode A, Kanabar DD, Muth A, Kunda NK, Mitragotri S, Gupta V* (2021). Bioinspired Particle Engineering for Non-invasive Drug Delivery to the Lungs. Materials Science & Engineering C 128:112324.

  37. Parvathaneni V, Elbatanony R, Goyal M, Chavan T, Vega N, Kolluru S, Muth A, Gupta V*, Kunda NK* (2021). Repurposing Bedaquiline for Effective Non-small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-based Molecular Inclusion Complexes. International Journal of Molecular Sciences 22(9):4783.

  38. Kulkarni NS, Vaidya B, Gupta V* (2021). Nano-synergistic Combination of Erlotinib and Quinacrine for Non-Small Cell Lung Cancer (NSCLC) Therapeutics – Evaluation in Biologically Relevant In-vitro Models. Materials Science and Engineering C 121:Feb 2021:111891.

 

Current Funding

  1. American Heart Association

  2. PulmoSIM Therapeutics